JCO Oncology Advances

Precision oncology in #Sarcoma

GemSarc, a 19-gene RNA signature, linked to longer gemcitabine treatment across 3 cohorts, with validation AUCs of 0.88 and 0.79. Promising for biomarker-guided chemotherapy; prospective validation needed.

Read the article. bit.ly/4zt45kI

Favezelimab/Pembrolizumab Co-formulation Versus Standard-of-Care in PD-L1-Positive Metastatic #ColorectalCancer: The Phase 3, Randomized KEYFORM-007 Study. Co-authored by @segaln.

Read the full article. bit.ly/4yVgywG

Impact of Neoadjuvant Carboplatin in Early-Stage Triple-Negative #BreastCancer: A Pooled Analysis of the BrighTNess, CALGB 40603 (Alliance), and GeparSixto Clinical
Trials.

Read the full article. bit.ly/4BATt4S
#bcsm

Addressing Cancer-Related Cognitive Impairment in #BreastCancer Survivors.

In a phase II single-arm trial, 16 survivors showed improvements in perceived cognition (+26.4 FACT-Cog PCI points) after 8 weeks of oxaloacetate.

Read the article. bit.ly/4etY1jx

Results from a Phase II Single Arm Trial Evaluating the Safety and Efficacy of Anhydrous Enol-Oxaloacetate on Improving Cognitive Complaints in Breast Cancer Survivors.

Read the full article. bit.ly/4etY1jx
#BreastCancer #bcsm